Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Organogenesis Holdings (ORGO) Invested Capital (2016 - 2025)

Historic Invested Capital for Organogenesis Holdings (ORGO) over the last 10 years, with Q3 2025 value amounting to $255.1 million.

  • Organogenesis Holdings' Invested Capital fell 1032.75% to $255.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $255.1 million, marking a year-over-year decrease of 1032.75%. This contributed to the annual value of $262.9 million for FY2024, which is 747.92% down from last year.
  • According to the latest figures from Q3 2025, Organogenesis Holdings' Invested Capital is $255.1 million, which was down 1032.75% from $233.2 million recorded in Q2 2025.
  • In the past 5 years, Organogenesis Holdings' Invested Capital ranged from a high of $315.4 million in Q4 2021 and a low of $227.3 million during Q1 2021
  • Its 5-year average for Invested Capital is $268.6 million, with a median of $268.7 million in 2023.
  • Its Invested Capital has fluctuated over the past 5 years, first surged by 8424.61% in 2021, then plummeted by 1472.8% in 2023.
  • Organogenesis Holdings' Invested Capital (Quarter) stood at $315.4 million in 2021, then fell by 14.33% to $270.2 million in 2022, then rose by 5.16% to $284.1 million in 2023, then decreased by 7.48% to $262.9 million in 2024, then decreased by 2.96% to $255.1 million in 2025.
  • Its Invested Capital was $255.1 million in Q3 2025, compared to $233.2 million in Q2 2025 and $242.9 million in Q1 2025.